uniQure (NASDAQ:QURE) Shares Gap Down – Time to Sell?

uniQure (NASDAQ:QURE)’s stock price gapped down prior to trading on Monday . The stock had previously closed at $12.47, but opened at $11.34. uniQure shares last traded at $10.38, with a volume of 548,019 shares traded.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. Mizuho lifted their target price on shares of uniQure from $7.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, December 19th. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price objective on shares of uniQure in a research note on Tuesday, March 4th. Raymond James raised shares of uniQure from an “outperform” rating to a “strong-buy” rating and increased their target price for the stock from $20.00 to $52.00 in a research report on Tuesday, December 10th. Guggenheim reaffirmed a “buy” rating on shares of uniQure in a research report on Wednesday, December 11th. Finally, Cantor Fitzgerald raised their price objective on uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research note on Tuesday, December 10th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $38.89.

uniQure Price Performance

The stock has a market cap of $554.83 million, a price-to-earnings ratio of -2.06 and a beta of 0.36. The stock has a fifty day simple moving average of $13.77 and a 200-day simple moving average of $10.83. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92.

Insider Buying and Selling

In related news, CFO Christian Klemt sold 10,438 shares of the company’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total value of $107,407.02. Following the completion of the transaction, the chief financial officer now directly owns 217,730 shares in the company, valued at approximately $2,240,441.70. This represents a 4.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Matthew C. Kapusta sold 28,341 shares of uniQure stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total transaction of $291,628.89. Following the sale, the chief executive officer now owns 651,454 shares in the company, valued at $6,703,461.66. This represents a 4.17 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 90,830 shares of company stock valued at $961,401. 4.74% of the stock is owned by company insiders.

Hedge Funds Weigh In On uniQure

Hedge funds and other institutional investors have recently made changes to their positions in the business. Avoro Capital Advisors LLC bought a new stake in uniQure in the fourth quarter valued at about $38,410,000. Franklin Resources Inc. grew its stake in shares of uniQure by 33.1% in the 4th quarter. Franklin Resources Inc. now owns 1,987,688 shares of the biotechnology company’s stock valued at $35,103,000 after purchasing an additional 494,726 shares during the period. Point72 Asset Management L.P. raised its holdings in shares of uniQure by 81.3% in the 4th quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company’s stock worth $31,282,000 after buying an additional 794,459 shares in the last quarter. Integral Health Asset Management LLC raised its holdings in shares of uniQure by 175.0% in the 4th quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company’s stock worth $19,426,000 after buying an additional 700,000 shares in the last quarter. Finally, RTW Investments LP lifted its position in shares of uniQure by 8,936.3% during the 4th quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company’s stock worth $15,958,000 after buying an additional 893,625 shares during the period. 78.83% of the stock is owned by institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.